Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment
Stopped early · Phase 1
Conditions studied: Hepatic Impairment
In brief
To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with moderate and severe hepatic impairment.
Key facts
- Study ID
- NCT02873650
- Run by
- Novartis Pharmaceuticals
- People needed
- 5
- Starts
- 2016-12-20
- Expected to finish
- 2019-04-08
- Last updated by the study team
- 2020-12-08
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- American Institute of Research — Los Angeles, California, United States
- Omega Research Consultants LLC — DeBary, Florida, United States
- Hassman Research Institute — Berlin, New Jersey, United States
- Wake Research Associates Oncology — Raleigh, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.